TNFSF10 and B-cell chronic lymphocytic leukemia: Although no marked changes in TRAIL expression were observed, further studies examining the functionality of this pathway could be conducted to determine whether the drug modulates the sensitivity of CLL cells to TRAIL‐mediated cell death.